AMRI Acquired by The Carlyle Group and GTCR
The Carlyle Group and GTCR have completed a previously announced acquisition of AMRI, a contract research and manufacturing organization.
On Aug. 31, 2017, the previously announced acquisition of AMRI was completed by affiliates of investment firms The Carlyle Group and Golder, Thomas, Cressey, Rauner (GTCR) for $21.75 per share in cash. AMRI president and CEO William S. Marth will continue leading the company.
Initially announced in June 2017, the agreement was unanimously approved by the AMRI board of directors, which had recommended that shareholders vote in favor of the transaction.
AMRI is a contract research and manufacturing organization with 25 years of experience in the pharmaceutical and biopharmaceutical industries. The company specializes in combining science and technology from start to finish of the drug discovery and development process. Its services include discovery, development, analytical and solid state services, and API manufacturing and drug product solutions.
Source: AMRI
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
